Quantbot Technologies LP Sells 1,439 Shares of Danaher Co. (NYSE:DHR)

Quantbot Technologies LP cut its holdings in Danaher Co. (NYSE:DHR) by 13.9% in the first quarter, HoldingsChannel reports. The firm owned 8,901 shares of the conglomerate’s stock after selling 1,439 shares during the quarter. Quantbot Technologies LP’s holdings in Danaher were worth $2,223,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of Danaher by 12.0% in the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Capital International Investors increased its position in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. Norges Bank purchased a new stake in Danaher during the 4th quarter valued at $1,752,382,000. Finally, Franklin Resources Inc. lifted its position in Danaher by 6.4% in the fourth quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after buying an additional 395,498 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.2 %

NYSE:DHR traded up $0.43 during trading hours on Friday, reaching $246.70. The company’s stock had a trading volume of 2,519,556 shares, compared to its average volume of 2,859,258. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company has a market capitalization of $182.73 billion, a P/E ratio of 41.81, a price-to-earnings-growth ratio of 3.70 and a beta of 0.83. The stock has a 50 day moving average price of $255.05 and a two-hundred day moving average price of $247.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the company posted $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Insider Activity

In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 148,783 shares of company stock worth $37,536,717. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and increased their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Citigroup increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Bank of America boosted their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Barclays increased their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Finally, Evercore ISI dropped their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $268.67.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.